Protagonist Therapeutics Inc’s filing revealed that its Chief Financial Officer Ali Asif unloaded Company’s shares for reported $0.63 million on Sep 11 ’24. In the deal valued at $44.49 per share,14,203 shares were sold. As a result of this transaction, Ali Asif now holds 34,960 shares worth roughly $1.64 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Waddill William D. sold 8,000 shares, generating $360,000 in total proceeds. Upon selling the shares at $45.00, the Director now owns 12,000 shares.
Before that, Ali Asif bought 14,203 shares. Protagonist Therapeutics Inc shares valued at $631,855 were divested by the Officer at a price of $44.49 per share.
TD Cowen initiated its Protagonist Therapeutics Inc [PTGX] rating to a Buy in a research note published on September 24, 2024; the price target was $65. A number of analysts have revised their coverage, including Truist’s analysts, who began to cover the stock in early September with a ‘”a Buy”‘ rating. CapitalOne began covering PTGX with “an Overweight” recommendation on October 30, 2023.
Price Performance Review of PTGX
On Friday, Protagonist Therapeutics Inc [NASDAQ:PTGX] saw its stock fall -0.11% to $46.97. Over the last five days, the stock has gained 4.19%. Protagonist Therapeutics Inc shares have risen nearly 104.84% since the year began. Nevertheless, the stocks have risen 216.08% over the past one year. While a 52-week high of $48.32 was reached on 10/15/24, a 52-week low of $13.72 was recorded on 01/05/24. SMA at 50 days reached $43.83, while 200 days put it at $33.39.
Levels Of Support And Resistance For PTGX Stock
The 24-hour chart illustrates a support level at 46.60, which if violated will result in even more drops to 46.22. On the upside, there is a resistance level at 47.44. A further resistance level may holdings at 47.90. The Relative Strength Index (RSI) on the 14-day chart is 61.37, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.73, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 24.40%. Stochastics %K at 76.02% indicates the stock is a holding.
How much short interest is there in Protagonist Therapeutics Inc?
A steep rise in short interest was recorded in Protagonist Therapeutics Inc stocks on 2024-09-30, growing by 0.24 million shares to a total of 3.52 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-30 was 3.28 million shares. There was a rise of 6.87%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on August 25, 2022 when JMP Securities began covering the stock and recommended ‘”a Mkt outperform”‘ rating along with a $21 price target.
